





Who we are

Gadea Pharmaceutical Group is an independent Spanish group of affiliated companies dedicated to technical development services, production and marketing of APIs. This group includes Ragactives, started in 1991 as an APIs development company, Crystal Pharma, founded in 1996, dedicating its activity to the production and marketing of steroids, and Solea Pharma, incorporated in 2005, a chemical plant taking advantage of intellectual property in Malta. Gadea Pharmaceutical Group, as the holding company, is encompassing the activity of the affiliated companies.

Gadea is managed and run by a team of professional chemists which have great experience and expertise in this type of products. More than 40% of our employees are qualified chemists and many of them hold doctorate degrees.



Business strategy

Based on the development and manufacturing of high quality active pharmaceutical ingredients for the most demanding regulated markets. From R&D to sterile quality, including Intellectual Property, customers are essential part of the business.

Manufacturing

Four multipurpose synthesis plants (one of them sterile), for commercial production with capacity ranges from milligrams for clinical studies, to multi-kilograms.

High quality products manufactured under strict cGMP conditions

Thorough control of all process steps, including wastes and emissions.

Technological development services

Well documented DMFs according to FDA and EU requirements.



Crystal pharma

The company's areas of interest, always associated with steroids, include: Research and Development, Chemical Synthesis of APIs, High Containment technology facility for production of sex hormones and Sterile filtered Crystallization and micronisation.

Synthesis Plant

Specialized in several kinds of fluorination reactions. The Preparation of current offered products involves up to one hundred and seventy different chemical reactions.

Volume reaction 40 m³ which allows to produce to capacity of 25 MT, both corticosteroids and progestins including those of highest potency.

Sterile Crystallization

Plant for the manufacture of sterile steroids by crystallization.

State-of-the-art technology avoids endotoxins and microorganism in products to be used for injectable suspensions, anti-asthmatic or ophthalmic use.

Equipped with a sterile microniser, specially designed to ensure the sterility of the products and to maintain the highest quality standards for the final product handling. Production capacity of this plant is 4 MT.

High Potency Steroids Hormone Unit

Based on containment engineering isolator technology, from lab scale to industrial production including micronisation, we are in the position to cater the market with high active sex hormones, produced under the safest conditions.

Successfully
inspected by the 





Development Services

Ragactives started its activities in the early nineties providing customers the opportunity to outsource their development needs.

Our current product portfolio proves our success in the development of innovative and economically viable synthesis routes for the production of these products.

About Us

Seamless process from Research at Development Laboratories, to K-Lab and Production of quality APIs developed and produced under GMP conditions.

Scale-up and industrialization: cGMP Kilo Lab and industrial plant. Robustness of industrial process

Analytical Resources: HPLC-MS, HPLC, GC, FT-IR, UV-Vis, Karl Fischer, Melting point determination.

NMR, GC-MS, TGA, Dif. R-X, DSC outsourced from Regional Universities.

Customized Synthesis

Multi-purpose reactors with volumes ranging from 160 L to 3.000 L and a total reaction volume of 7.000 L.

Close loop supplying Millipore USP purified water to all the reactors.

Our Strengths

Expertise in Chemical Development. A solid intellectual property base, which includes patents and patent applications related to novel synthetic routes, finishing and analytical methodologies.



Successfully  inspected by the



Solea Pharma

R&D developed and transferred by Ragactives, Solea Pharma production unit, located in Malta, offers an attractive patent position and a well established Quality System.

Main goal is to provide an incentive for generic manufacturers, to file certifications challenging patents that may be invalid, not infringed by the product that is the subject of the ANDA.





gadea
Pharmaceutical Group

Parque Tecnológico de Boecillo • Parcela 113

47151 Boecillo, Valladolid (Spain) EU

T.: +34 983 54 80 72 • Fax: +34 983 54 81 13

gadea@gadea.com

www.gadea.com